Search for Current Clinical Trials

Study Name Description Trial Category Trial SubCategory
A032002 The purpose of this study is to compare immunotherapy alone vs immunotherapy in combination with radiation for patients with metastatic Urothelial cancer. Cancer Metastatic Urothelial
A032103 The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. Cancer Urothelial
EA8211 This study is for patients with renal cell cancer who have a total of 2-5 metastatic lesions. The study is looking at using radiation to the metastatic sites in combination with chemotherapy. Cancer Metastatic Renal Cell
EAY191-N5 This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. Cancer Her2+ Solid Tumors
S2101 This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. Cancer Melanoma
Tandem The purpose of this study is to compare the effects of the study drug, obicetrapib when administered together with the drug ezetimibe as a fixed dose combination. A fixed dose combination means the two drugs are combined into a single tablet. The study will also check how safe obicetrapib and ezetimibe is for participants with high levels of LDL-C in the blood. Heart & Vascular Lipid Management; Cardiovascular Disease
SOUL Music This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent. Eligible participants in the randomization trial will be randomized to ureteroscopy with stent placement or stent omission. Eligible participants that consent to the observational only cohort will complete surveys and the treating physicians will decide the treatment options for the participants. Surgery Urinary Stone Disease
EAY191-E5 This study is for patients who have a KRAS G12C mutation and advanced/metastatic solid tumors. Your cancer must have progressed on standard of care therapy. You cannot have colorectal cancer or non-small cell lung cancer. Cancer Solid Tumors
S2013 The purpose of this study is the look at the side effects of immunotherapy treatment. You must be starting immunotherapy alone not in combination with other treatments. You must have a solid tumor. Cancer Solid Tumors
Intuitive Surgical Ureter The purpose of this study is to investigate whether the study drug may allow the surgeon to better see the ureters when using the da Vinci Surgical System for gynecological surgery. Surgery Gynecology
NRG-BR009 The purpose of this study is treat breast cancer after surgery. You must have estrogen positive breast cancer and an oncotype score ≤25. This study looks at adding chemotherapy to the standard treatment of ovarian function suppression and aromatase inhibitor. Cancer Breast
GU012 The purpose of this study is to compare standard immunotherapy with immunotherapy and radiation. You must be diagnosed with metastatic renal cell cancer and have not had surgery for this cancer. Cancer Metastatic Renal Cell
S2209 This study is for frail-intermediately fit newly diagnosed multiple myeloma patients. Your current lab values will be used to determine if you qualify for this study. This study compares different chemo regimens to determine the effectiveness of them. Cancer Multiple Myeloma
A031701 The purpose of this study is to compare standard or dose dense gemcitabine and cisplatin chemo. You must have been diagnosed with muscle invasive bladder cancer. Cancer Bladder
A031702 The purpose of this study is to look at the effectineness of cabozantinib combined with nivolumab and ipilimubmab. You must be diagnosed with a rare genitourinary tumor of the kidney, bladder, ureters or penis. Cancer Rare Genitourinary
A031704 The purpose of this study is to compare overall survival in patients treated with ipilimumab-nivolumab followed by either nivolumab or cabozantinib-nivolumab. You must be diagnosed with metastatic renal cell cancer. Cancer Metastatic Renal Cell
A031902 The purpose of this study is to evaluate progression free survival and overall survival with the use of enzalutamide and rucaparib vs enzalutamide alone. You must be diagnosed with metastatic castration-resistant prostate cancer. This must be your first treatment for your metastatic cancer. Cancer Metastatic Prostate
A081801 (sub study A151216) The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC). Cancer Non-Small Cell Lung
A082002 The purpose of this study is to determine in SBRT (stereotactic body radiation therapy) improves survival in advanced stage NSCLC. You must be diagnosed with stage 3 or 4 Non-Small Cell Lung Cancer (NSCLC). Cancer Non-Small Cell Lung
A212102 This is a study looking at determining effectiveness of a multicancer early dectection blood test. Participants are healthy subjects, those with a known cancer diagnosis, and those with high suspicion of cancer. Cancer All tumor types
EA2183 The purpose of this study is to determine if adding radiation to chemo is beneficial. You must be diagnosed with metastatic HER2 negative esophageal and gastric cancer. Cancer Esophageal
EA5182 This study is comparing Osimertinib and Bevacizumab vs Osimertinib alone as first-line treatment for patients with metastatic EGFR mutant Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 3 or 4 NSCLC. Cancer Non-Small Cell Lung
EAA173 The purpose of this study is determine if dararumumab enhances the effectiveness of revlimid in patients with smoldering myeloma. You must be diagnosed with asymptomatic high risk smoldering multiple myeloma. Cancer Smoldering Myeloma
EAA181 The purpose of this study is to determine what consolidation regimen is most effective. Patients cannot get stem cell transplant until first relapse or later. You must have newly diagnosed multiple myeloma (MM). Cancer Multiple Myeloma
EAY191 ComboMATCH The purpose of this study is to find targeted therapy for specific gene mutations in metastatic or advanced cancer. You must have progressed on standard of care treatment or have a cancer which has no standard of care treatment. If select mutations are found you may be eligible for a sub-study. Cancer Genomics
EAY191-A6 ComboMATCH The purpose of this study is to see if adding Binimetinib in combination with FOLFOX is more effective treatment. You must be diagnosed with biliary tract cancer with a MAPK pathway gene mutation. Cancer Biliary
EAY191-E4 ComboMATCH The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. Cancer Solid Tumors
EAY191-N2 ComboMATCH This study is for people diagnosed with hormone receptor positive breast cancer that has spread. A NF1 gene mutation must exist. Cancer Metastatic Breast
EAY191-N4 The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation. Cancer Ovarian & Endometrial
EAY191-S3 ComboMATCH The purpose of this study is to determine the effectiveness of Paclitaxel and Ipatasertib in patients who progressed within 6 months of taxane-based therapy. You must have a a AKT-Altered cancer. You must have a locally advanced, unresectable or metastatic cancer. Cancer Solid Tumors (non-breast)